Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

Molecular Neurobiology

Volumn 52, Issue 2, 2015, Pages 846-858

  Requejo, C ^a   Ruiz Ortega, J A ^a   Bengoetxea, H ^a   Garcia Blanco, A ^a   Herran E ^a,b   Aristieta, A ^a   Igartua, M ^a,b   Ugedo, L ^a   Pedraz, J L ^a,b   Hernandez R M ^a,b   Lafuente, J V ^a,c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

6 OHDA; GDNF; Neuroregeneration; Parkinson s disease; Rostro caudal gradient; VEGF

Indexed keywords

BROXURIDINE; DESIPRAMINE; DOUBLECORTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NANOSPHERE; OXIDOPAMINE; PARGYLINE; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN; DOUBLECORTIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NANOCAPSULE; NERVE PROTEIN; NEUROPEPTIDE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN PROTECTION; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NANOENCAPSULATION; NEUROANATOMY; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; ANIMAL; CHEMISTRY; COMBINATION DRUG THERAPY; DNA REPLICATION; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; GLIA; INTRALESIONAL DRUG ADMINISTRATION; NERVE CELL; PARKINSONIAN DISORDERS; PATHOLOGY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

ANIMALS; CORPUS STRIATUM; DNA REPLICATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INJECTIONS, INTRALESIONAL; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NANOCAPSULES; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONS; NEUROPEPTIDES; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TYROSINE 3-MONOOXYGENASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940794297     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9234-y     Document Type: Article

References (47)

1. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744–1754
2. Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson’s disease. Neurology 72:1–136
3. Gibb WR (1997) Functional neuropathology in Parkinson’s disease. Eur Neurol 38(Suppl 2):21–25
4. Herrán E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, Ugedo L, Pedraz JL, Lafuente JV, Hernández RM (2014) Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease. Int J Nanomedicine 9:2677–2687
5. Franco V, Turner RS (2012) Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signs. Neurobiol Dis 47:114–1125
6. Bayer SA (1984) Neurogenesis in the rat neostriatum. Int J Dev Neurosci 2:163–175
7. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16:653–661
8. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55–66
9. Herrán E, Ruiz-Ortega JÁ, Aristieta A, Igartua M, Requejo C, Lafuente JV, Ugedo L, Pedraz JL, Hernández RM (2013) In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease. Eur J Pharm Biopharm 85:1183–1190
10. Morera-Herreras T, Ruiz-Ortega JA, Linazasoro G, Ugedo L (2011) Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. Psychopharmacol (Berl) 214:379–389
11. Paxinos G, Watson C (1997) The rat brain in steretaxic coordinates. Academic, San Diego
12. Bjorklund A, Winkler C, Rosenblad C, Kirik D (1997) Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson’s disease. Neurobiol Dis 4:186–200
13. Przedborski S, Levivier M, Kostic V, Jackson-Lewis V, Dollison A, Gash DM, Fahn S, Cadet JL (1991) Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence. Brain Res 550:231–238
14. Brodkey JA, Gates MA, Laywell ED, Steindler DA (1993) The complex nature of interactive neuroregeneration-related molecules. Exp Neurol 123:251–270
15. Clarke LE, Barres BA (2013) Emerging roles of astrocytes in neural circuit development. Nat Rev Neurosci 14:311–321
16. Fuller HR, Hurtado ML, Wishart TM, Gates MA (2014) The rat striatum responds to nigro-striatal degeneration via the increased expression of proteins associated with growth and regeneration of neuronal circuitry. Proteome Sci 28;12:20
17. Barcia C, Bautista V, Sánchez-Bahillo A, Fernández-Villalba E, Faucheux B, Poza y Poza M, Fernandez Barreiro A, Hirsch EC, Herrero MT (2005) Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112:1237–1248
18. Block ML, Li G, Qin L, Wu X, Pei Z, Wang T (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 20:251–258
19. Sarre S, Yuan H, Jonkers N, Van Hemelrijck A, Ebinger G, Michotte Y (2004) In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine lesioned rats. J Neurochem 90:29–39
20. Agid Y, Javoy F, Glowinski J (1973) Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 245:150–151
21. Jankovic J, Shoulson I, Weiner WJ (1994) Early-stage Parkinson’s disease: to treat or not to treat. Neurology 44(Suppl 1):4–7
22. Li Z, Decavel C, Hatton GI (1995) Calbindin-D28k: role in determining intrinsically generated firing patterns in rat supraoptic neurones. J Physiol 488:601–608
23. Hurley MJ, Brandon B, Gentleman SM, Dexter DT (2013) Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136:2077–2097
24. Cervós-Navarro J, Lafuente JV (1991) Traumatic brain injuries: structural changes. J Neurol Sci 103:S3–S14
25. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2011) The origins of oxidant stress in Parkinson’s disease and therapeutic strategies. Antioxid Redox Signal 14:1289–1301
26. Jollivet C, Aubert-Pouessel A, Clavreul A, Venier-Julienne MC, Montero-Menei CN, Benoit JP, Menei P (2004) Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson’s disease. Neurosci Lett 356:207–210
27. Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ (2009) Effective GDNF brain delivery using microspheres—a promising strategy for Parkinson’s disease. J Control Release 135:119–126
28. Rosenblad C, Kirik D, Bjorklund A (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp Neurol 161:503–516
29. Tufro A, Teichman J, Banu N, Villegas G (2007) Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 358:410–416
30. Yasuhara T, Shing T, Kobayashi K et al (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson’s disease. Eur J Neurosci 19:1494–1504
31. Harrigan MR, Ennis SR, Sullivan SE, Keep RF (2003) Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochir (Wien) 145:49–53
32. Rite I, Machado A, Cano J, Venero JL (2007) Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 101:1567–1582
33. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling—in control of vascular function. Nat Rev Mol Cell Biol 7:359–371
34. Falk T, Gonzalez RT, Sherman SJ (2010) The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson’s disease. Int J Mol Sci 11:2875–2900
35. Birling MC, Price J (1995) Influence of growth factors on neuronal differentiation. Curr Opin Cell Biol 7:878–847
36. Schwartz PM, Borghesani PR, Levy RL, Pomeroy SL, Segal RA (1997) Abnormal cerebellar development and foliation in BDNF−/− mice reveals a role for neurotrophins in CNS patterning. Neuron 19:269–281
37. Xiong N, Zhang Z, Huang J, Chen C, Zhang Z, Jia M, Xiong J, Liu X, Wang F, Cao X, Liang Z, Sun S, Lin Z, Wang T (2011) VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene Ther 18:394–402
38. Sopova K, Gatsiou K, Stellos K, Laske C (2014) Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer’s disease: from pathophysiology to novel treatment strategies. Curr Alzheimer Res 11:27–39
39. Pellegrini L, Bennis Y, Guillet B, Velly L, Garrigue P, Sabatier F, Dignat-George F, Bruder N, Pisano P (2013) Therapeutic benefit of a combined strategy using erythropoietin and endothelial progenitor cells after transient focal cerebral ischemia in rats. Neurol Res 35:937–947
40. Gittis AH, Hang GB, LaDow ES, Shoenfeld LR, Atallah BV, Finkbeiner S, Kreitzer AC (2011) Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine. Neuron 71:858–868
41. Batchelor PE, Liberatore GT, Porritt MJ, Donnan GA, Howells DW (2000) Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur J Neurosci 12:3462–3468
42. Lindvall O, Björklund A, Skagerberg G (1984) Selective histochemical demonstration of dopamine terminal systems in rat di- and telencephalon: new evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei. Brain Res 306:19–30
43. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303–317
44. Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, Mount DW, Wüllner U, Sherman SJ, Falk T (2014) Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson’s disease. Neuroscience 258:385–400
45. Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A (1999) Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 11:1554–1566
46. García-Amado M, Prensa L (2013) Distribution of dopamine transporter immunoreactive fibers in the human amygdaloid complex. Euro J Neurosci 38:3589–3601
47. Ortuzar N, Rico-Barrio I, Bengoetxea H, Argandoña EG, Lafuente JV (2013) VEGF reverts the cognitive impairment induced by a focal traumatic brain injury during the development of rats raised under environmental enrichment. Behav Brain Res 246:36–46